FGF23 & Phosphate Disorders; Osteoporosis risk factors


The First Multi-Dose Trial of a Human Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH)
Erik Allen Imel, Xiaoping Zhang, Mary Denise Ruppe, Thomas Joseph Weber, Mark Klausner, Takahiro Ito, Maria Vergeire, Jeffrey Humphrey, Francis H Glorieux, Anthony A Portale, Karl Insogna, Munro Peacock and Thomas O Carpenter


FGF23-Mediated Vitamin D Metabolism in Tumor-Induced Osteomalacia
Diala El-Maouche, Martin Kaufmann, Rachel I Gafni, Glenville Jones and Michael T. Collins


Fibroblast Growth Factor 23 Is Not Associated with Age-Related Changes in Phosphate Handling in Children
Deborah M Mitchell, Harald W Jueppner and Sherri-Ann M Burnett-Bowie


Increased Risk for Vertebral Fractures with Long-Term Observation in Mild Primary Hyperparathyroidism: Five Year Data from the Scandinavian Investigation of Primary Hyperparathyroidism (SIPH)
Karolina Lundstam, Mikael Hellström, Ansgar Heck, Kristin Godang, Marek Baranowski, Jan Erik Varhaug, Charlotte L Mollerup, Thord P Rosen, Jörgen Nordenström, Svante Jansson and Jens Bollerslev


Increased Bone Mineral Content in Patients with Congenital Generalized Lipodystrophy Is Unaffected By Metreleptin Replacement Therapy
John D. Christensen, Andreea O. Lungu, Elaine Cochran, Michael T. Collins, Rachel I Gafni, James C Reynolds, Phillip Gorden and Rebecca J. Brown